1581692-25-2

Upstream product

• 1581692-34-3 2-(6-tert-butyl-1-oxo-1H-phthalazin-2-yl)-6-chlorobenzaldehyde 
• 1385022-16-1 6-tert-butyl-2-(3-chloro-2-hydroxymethylphenyl)-2H-phthalazin-1-one 
• 1581692-35-4 acetic acid 2-(6-tert-butyl-1-oxo-1H-phthalazin-2-yl)-6-chlorobenzyl ester 
• 1360056-64-9 6-chloro-4-(1'-ethyl-1',2',3',4',5',6'-hexahydro-[3,4']bipyridinyl-6-ylamino)-2-methyl-2H-pyridazin-3-one 
• 1413063-68-9 acetic acid 2-(6-tert-butyl-1-oxo-1H-phthalazin-2-yl)-6-(4,4,5,5-tetramethyl[1,3,2]dioxaborolan-2-yl)benzyl ester 
• 1385022-22-9 2,5-di-tert-butyl-3-hydroxy-2,3-dihydro-isoindol-1-one 
• 349407-89-2 4-(tert-butyl)-N-(tert-butyl)benzamide 
• 1385022-20-7 6-tert-butyl-2H-phthalazin-1-one 
• 1710-98-1 p-tert-butyl benzoyl chloride 

Relevant academic research and scientific papers

INHIBITORS OF BRUTON'S TYROSINE KINASE

This application discloses compounds according to generic Formula I: wherein all variables are defined as described herein, which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of Formula I and at least one carrier, diluent or excipient.